| Name | inS3-54A18 |
| Description | inS3-54A18 is an effective inhibitor of STAT3. inS3-54A18 has anticancer effects. |
| In vitro | inS3-54A18 selectively impedes STAT3's interaction with its inherent target sequences and diminishes the expression of genes downstream of STAT3. It significantly reduces the wound healing capacity in A549 and MDA-MB-231 cells to 64% and 76% at a concentration of 5μM, and further decreases healing to 47% and 39%, respectively, at 10μM. Notably, inS3-54A18 does not interfere with either the basal or IL-6-stimulated activation of STAT3, but specifically inhibits the expression of a STAT3 target gene, survivin. |
| In vivo | inS3-54A18 (200 mg/kg, p.o.) inhibits tumor growth, metastasis, and STAT3 target gene expression in an A549 cell mouse xenograft model[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 150 mg/mL (401.25 mM)
|
| Keywords | Inhibitor | inS-3-54A18 | inS3 54A18 | inS3-54A18 | inS354A18 | inhibit | STAT |
| Inhibitors Related | Nifuroxazide | Balsalazide sodium hydrate | Fludarabine | Scutellarin | Niclosamide | 2-(1,8-naphthyridin-2-yl)phenol | CASIN | Diosgenin | Niclosamide olamine | Artesunate | Alantolactone | Stattic |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Anti-Cancer Metabolism Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Liver Cancer Compound Library | Anti-Cancer Active Compound Library | Transcription Factor-Targeted Compound Library |
United States
